{"url_path":"/sec/phge/8-k/2026-07-02/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/1739174/0001213900-26-075072-index.html","accession_number":"0001213900-26-075072","cik":"0001739174","ticker":"PHGE","issuer_name":"BiomX Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1739174/0001213900-26-075072-index.html","primary_entity_key":"0001739174","primary_entity_name":"BiomX Inc."},"word_count":96,"has_tables":true,"body_markdown":"** **\n\n**Item 9.01 Financial Statements and Exhibits.**\n\n* *\n\n*(d) Exhibits*\n\n* *\n\n**Exhibit No.**\n \n**Description**\n\n16.1\n \n[Letter from Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, to the Securities and Exchange Commission.](ea029693401ex16-1.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n****\n\n** **\n\n1\n\n \n\n****\n\n** **\n\n**SIGNATURE**\n\n** **\n\nPursuant to the requirements of the Securities Exchange Act of 1934,\nthe registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized..\n\n \n\n \nBIOMX INC\n\n \n \n \n\n \nDate: July 2, 2026\n\n \n \n \n\n \nBy:\n/s/ Michael Oster\n\n \nName:\nMichael Oster\n\n \nTitle:\nChief Executive Officer\n\n \n \n \n\n \n\n2"}